About the Company
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $MRNA News
Moderna CEO’s compensation dropped in 2023
Moderna Inc. CEO Stephane Bancel's total compensation was down about 12% in 2023 compared to the year prior as the company ...
What's Going On With Moderna Stock On Monday?
Recently, on clinicaltrials.gov, Merck & Co Inc (NYSE:MRK) posted a new trial of Moderna Inc’s (NASDAQ:MRNA) V940, an ...
Moderna falls just short of 2023 hiring goals. But it's still hiring
Last year, Moderna Inc. CEO Stéphane Bancel told investors at the J.P. Morgan Healthcare Conference that the company planned to hire another 2,000 employees in 2023, and that the vast majority ...
Moderna, Inc. (NASDAQ:MRNA) institutional owners may be pleased with recent gains after 25% loss over the past year
After a year of 25% losses, last week’s 8.4% gain would be welcomed by institutional investors as a possible sign that ...
Moderna, BioNTech Stocks Rise on New mRNA Possibilities
The pandemic validated the disease-fighting prowess of mRNA vaccines. Shares of Moderna and BioNTech rose on Monday after two ...
Moderna, Inc. (NASDAQ:MRNA) Q4 2023 Earnings Call Transcript
Moderna, Inc. (NASDAQ:MRNA) Q4 2023 Earnings Call Transcript February 22, 2024 Moderna, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details ...
Moderna’s stock pops after surprise quarterly profit, even as COVID sales continue to slide
Moderna Inc. shares MRNA, +3.57% jumped more than 7% premarket on Thursday after the company reported a surprise fourth-quarter profit, even as its COVID product sales continue to plunge.
Moderna stock rises as COVID shot gains market share on Pfizer
Moderna Inc. shares shot up in early trading after the company reported fourth-quarter revenue that beat analysts’ expectations by gaining COVID vaccine market share on its rival, Pfizer Inc ...
Moderna ready to take its next jab at success
T he share price chart of Moderna is enough to make even the steeliest investor feel a bit seasick. Nevertheless, its rise to ...
moderna inc.
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low. Moderna says its updated coronavirus ...
Moderna, Inc.: Moderna Earnings: Several Phase 3 Readouts and RSV Launch in 2024 Support Our Fair Value Estimate
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine ...
Moderna - Giubiasco head to head game preview and prediction
Moderna vs Giubiasco team performances, predictions and head to head team stats for goals, first half goals, corners, cards.
Loading the latest forecasts...